Chronic Idiopathic Constipation Market Research Report Information By Diagnosis (Blood Tests, Sigmoidoscopy, Colonoscopy, Balloon Expulsion Test, Anorectal Manometry), Treatment (Drugs), End-User (Hospitals & Clinics, Diagnostic Centers) -Forecast Till 2032

Table of Content

1. Report Prologue

2. Market Introduction

2.1 Definition

2.2 Scope of the Study

2.2.1 Research Objective

2.2.2 Assumptions

2.2.3 Limitations

3. Research Methodology

3.1 Introduction

3.2 Primary Research

3.3 Secondary Research

3.4 Market Size Estimation

4. Market Dynamics

4.1 Drivers

4.2 Restraints

4.3 Opportunities

4.4 Challenges

4.5 Macroeconomic Indicators

4.6 Technology Trends & Assessment

5. Market Factor Analysis

5.1 Porter’s Five Forces Analysis

5.1.1 Bargaining Power of Suppliers

5.1.2 Bargaining Power of Buyers

5.1.3 Threat of New Entrants

5.1.4 Threat of Substitutes

5.1.5 Intensity of Rivalry

5.2 Value Chain Analysis

5.3 Investment Feasibility Analysis

5.4 Pricing Analysis

6. Global Chronic Idiopathic Constipation Market, by Diagnosis

6.1 Introduction

6.2 Blood Tests

6.2.1 Market Estimates & Forecast, 2020–2027

6.3 Sigmoidoscopy

6.3.1 Market Estimates & Forecast, 2020–2027

6.4 Colonoscopy, Balloon Expulsion Test

6.4.1 Market Estimates & Forecast, 2020–2027

6.5 Balloon Expulsion Test

6.5.1 Market Estimates & Forecast, 2020–2027

6.6 Others

7. Global Chronic Idiopathic Constipation Market, by Treatment

7.1 Introduction

7.2 Drug

7.2.1 Market Estimates & Forecast, 2020–2027

7.3 Surgery

7.3.1 Market Estimates & Forecast, 2020–2027

8. Global Chronic Idiopathic Constipation Market, by End-User

8.1 Introduction

8.2 Hospitals & Clinics

8.2.1 Market Estimates & Forecast, 2020–2027

8.3 Gastroenterology Clinics

8.3.1 Market Estimates & Forecast, 2020–2027

8.4 Diagnostic Centers

8.4.1 Market Estimates & Forecast, 2020–2027

9. Global Chronic Idiopathic Constipation Market, by Region

9.1 Introduction

9.2 Americas

9.2.1 North America

9.2.1.1 U.S.

9.2.1.1 Canada

9.2.2 South America

9.3 Europe

9.3.1 Western Europe

9.3.1.1 Germany

9.3.1.2 France

9.3.1.3 U.K.

9.3.1.4 Italy

9.3.1.5 Spain

9.3.1.6 Rest of Western Europe

9.3.2 Eastern Europe

9.4 Asia Pacific

9.4.1 Japan

9.4.2 China

9.4.3 India

9.4.4 Australia

9.4.5 Republic of Korea

9.4.6 Rest of Asia Pacific

9.5 The Middle East & Africa

9.5.1 United Arab Emirates

9.5.2 Saudi Arabia

9.5.3 Oman

9.5.4 Kuwait

9.5.5 Qatar

9.5.6 Rest of the Middle East & Africa

10 Company Landscape

10.1 Introduction

10.2 Market Share Analysis

10.3 Key Development & Strategies

10.3.1 Key Developments

11 Company Profiles

11.1 Actavis

11.1.1 Company Overview

11.1.2 Product Overview

11.1.3 Financials

11.1.4 SWOT Analysis

11.2 Chugai Pharmaceutical

11.2.1 Company Overview

11.2.2 Product Overview

11.2.3 Financial Overview

11.2.4 Key Developments

11.2.5 SWOT Analysis

11.3 Progenics Pharmaceuticals

11.3.1 Company Overview

11.3.2 Product Overview

11.3.3 Financial Overview

11.3.4 Key Development

11.3.5 SWOT Analysis

11.4 F. Hoffmann-La Roche AG

11.4.1 Company Overview

11.4.2 Product/Business Segment Overview

11.4.3 Financial Overview

11.4.4 Key Development

11.4.5 SWOT Analysis

11.5 Boehringer Ingelheim GmbH

11.5.1 Company Overview

11.5.2 Product Overview

11.5.3 Financial overview

11.5.4 Key Developments

11.6 Pfizer Inc

11.6.1 Company Overview

11.6.2 Product Overview

11.6.3 Financial Overview

11.6.4 Key Developments

11.7 GlaxoSmithKline

11.7.1 Overview

11.7.2 Product Overview

11.7.3 Financials

11.7.4 Key Developments

11.7.5 SWOT Analysis

11.8 Others

13 MRFR Conclusion

13.1 Key Findings

13.1.1 From CEO’s View Point

13.1.2 Unmet Needs of the Market

13.2 Key Companies to Watch

13.3 Prediction of the Chronic Idiopathic Constipation Industry

14 Appendix

LIST OF TABLES

Table 1 Chronic Idiopathic Constipation Industry Synopsis, 2020–2027

Table 2 Global Chronic Idiopathic Constipation Market Estimates & Forecast, 2020–2027, (USD Million)

Table 3 Global Chronic Idiopathic Constipation Market, by Region, 2020–2027, (USD Million)

Table 4 Global Chronic Idiopathic Constipation Market, by Diagnosis, 2020–2027, (USD Million)

Table 5 Global Chronic Idiopathic Constipation Market, by Treatment, 2020–2027, (USD Million)

Table 6 Global Chronic Idiopathic Constipation Market, by End-User, 2020–2027, (USD Million)

Table 7 North America Chronic Idiopathic Constipation Market, by Diagnosis, 2020–2027, (USD Million)

Table 8 North America Chronic Idiopathic Constipation Market, by Treatment, 2020–2027, (USD Million)

Table 9 North America Chronic Idiopathic Constipation Market, by End-User, 2020–2027, (USD Million)

Table 10 U.S. Chronic Idiopathic Constipation Market, by Diagnosis, 2020–2027, (USD Million)

Table 11 U.S. Chronic Idiopathic Constipation Market, by Treatment, 2020–2027, (USD Million)

Table 12 U.S. Chronic Idiopathic Constipation Market, by End-User, 2020–2027, (USD Million)

Table 13 Canada Chronic Idiopathic Constipation Market, by Diagnosis, 2020–2027, (USD Million)

Table 14 Canada Chronic Idiopathic Constipation Market, by Treatment, 2020–2027, (USD Million)

Table 15 Canada Chronic Idiopathic Constipation Market, by End-User, 2020–2027, (USD Million)

Table 16 South America Chronic Idiopathic Constipation Market, by Diagnosis, 2020–2027, (USD Million)

Table 17 South America Chronic Idiopathic Constipation Market, by Treatment, 2020–2027, (USD Million)

Table 18 South America Chronic Idiopathic Constipation Market, by End-User, 2020–2027, (USD Million)

Table 19 Europe Chronic Idiopathic Constipation Market, by Diagnosis, 2020–2027, (USD Million)

Table 20 Europe Chronic Idiopathic Constipation Market, by Treatment, 2020–2027, (USD Million)

Table 21 Europe Chronic Idiopathic Constipation Market, by End-User, 2020–2027, (USD Million)

Table 22 Western Europe Chronic Idiopathic Constipation Market, by Diagnosis, 2020–2027, (USD Million)

Table 23 Western Europe Chronic Idiopathic Constipation Market, by Treatment, 2020–2027, (USD Million)

Table 24 Western Europe Chronic Idiopathic Constipation Market, by End-User, 2020–2027, (USD Million)

Table 25 Eastern Europe Chronic Idiopathic Constipation Market, by Diagnosis, 2020–2027, (USD Million)

Table 26 Eastern Europe Chronic Idiopathic Constipation Market, by Treatment, 2020–2027, (USD Million)

Table 27 Eastern Europe Chronic Idiopathic Constipation Market, by End-User, 2020–2027, (USD Million)

Table 28 Asia Pacific Chronic Idiopathic Constipation Market, by Diagnosis, 2020–2027, (USD Million)

Table 29 Asia Pacific Chronic Idiopathic Constipation Market, by Treatment, 2020–2027, (USD Million)

Table 30 Asia Pacific Chronic Idiopathic Constipation Market, by End-User, 2020–2027, (USD Million)

Table 31 Middle East & Africa Chronic Idiopathic Constipation Market, by Diagnosis, 2020–2027, (USD Million)

Table 32 Middle East & Africa Chronic Idiopathic Constipation Market, by Treatment, 2020–2027, (USD Million)

Table 33 Middle East & Africa Chronic Idiopathic Constipation Market, by End-User, 2020–2027, (USD Million)

LIST OF FIGURES

Figure 1 Research Process

Figure 2 Segmentation for the Global Chronic Idiopathic Constipation Market

Figure 3 Segmentation Market Dynamics for the Chronic Idiopathic Constipation Market

Figure 4 Global Chronic Idiopathic Constipation Market Share, by Diagnosis 2020

Figure 5 Global Chronic Idiopathic Constipation Market Share, by Treatment 2020

Figure 6 Global Chronic Idiopathic Constipation Market Share, by End-User, 2020

Figure 7 Global Chronic Idiopathic Constipation Market Share, by Region, 2020

Figure 8 North America Chronic Idiopathic Constipation Market Share, by Country, 2020

Figure 9 Europe Chronic Idiopathic Constipation Market Share, by Country, 2020

Figure 10 Asia Pacific Chronic Idiopathic Constipation Market Share, by Country, 2020

Figure 11 Middle East & Africa Chronic Idiopathic Constipation Market Share, by Country, 2020

Figure 12 Global Chronic Idiopathic Constipation Market: Company Share Analysis, 2020 (%)

Figure 13 Actavis: Key Financials

Figure 14 Actavis: Segmental Revenue

Figure 16 Actavis: Geographical Revenue

Figure 17 Chugai Pharmaceutical: Key Financials

Figure 18 Chugai Pharmaceutical: Segmental Revenue

Figure 19 Chugai Pharmaceutical: Geographical Revenue

Figure 20 Ferring International Center S.A: Key Financials

Figure 21 Ferring International Center S.A: Segmental Revenue

Figure 22 Ferring International Center S.A: Geographical Revenue

Figure 23 F. Hoffmann-La Roche AG: Key Financials

Figure 24 F. Hoffmann-La Roche AG: Segmental Revenue

Figure 25 F. Hoffmann-La Roche AG: Geographical Revenue

Figure 26 Progenics Pharmaceuticals: Segmental Revenue

Figure 27 Progenics Pharmaceuticals: Geographical Revenue

Figure 28 Progenics Pharmaceuticals. Key Financials

Figure 29 Boehringer Ingelheim GmbH. Segmental Revenue

Figure 30 Boehringer Ingelheim GmbH. Geographical Revenue

Figure 31 Boehringer Ingelheim GmbH: Key Financials

Figure 32 Pfizer, Inc.: Key Financials

Figure 33 Pfizer, Inc.: Segmental Revenue

Figure 34 Pfizer, Inc.: Geographical Revenue